235 related articles for article (PubMed ID: 28418883)
1. Downregulation of Bmi1 in breast cancer stem cells suppresses tumor growth and proliferation.
Srinivasan M; Bharali DJ; Sudha T; Khedr M; Guest I; Sell S; Glinsky GV; Mousa SA
Oncotarget; 2017 Jun; 8(24):38731-38742. PubMed ID: 28418883
[TBL] [Abstract][Full Text] [Related]
2. The BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cells.
Mayr C; Wagner A; Loeffelberger M; Bruckner D; Jakab M; Berr F; Di Fazio P; Ocker M; Neureiter D; Pichler M; Kiesslich T
Oncotarget; 2016 Jan; 7(1):745-58. PubMed ID: 26623561
[TBL] [Abstract][Full Text] [Related]
3. A miR-200c/141-BMI1 autoregulatory loop regulates oncogenic activity of BMI1 in cancer cells.
Dimri M; Kang M; Dimri GP
Oncotarget; 2016 Jun; 7(24):36220-36234. PubMed ID: 27105531
[TBL] [Abstract][Full Text] [Related]
4. BMI1 Inhibitors Down-regulate NOTCH Signaling and Suppress Proliferation of Acute Leukemia Cells.
Ohtaka M; Itoh M; Tohda S
Anticancer Res; 2017 Nov; 37(11):6047-6053. PubMed ID: 29061784
[TBL] [Abstract][Full Text] [Related]
5. BMI1 and PTEN are key determinants of breast cancer therapy: A plausible therapeutic target in breast cancer.
M JR; S V
Gene; 2018 Dec; 678():302-311. PubMed ID: 30096458
[TBL] [Abstract][Full Text] [Related]
6. PTC209, a Specific Inhibitor of BMI1, Promotes Cell Cycle Arrest and Apoptosis in Cervical Cancer Cell Lines.
Li J; Vangundy Z; Poi M
Anticancer Res; 2020 Jan; 40(1):133-141. PubMed ID: 31892561
[TBL] [Abstract][Full Text] [Related]
7. Bmi1 regulates self-renewal and epithelial to mesenchymal transition in breast cancer cells through Nanog.
Paranjape AN; Balaji SA; Mandal T; Krushik EV; Nagaraj P; Mukherjee G; Rangarajan A
BMC Cancer; 2014 Oct; 14():785. PubMed ID: 25348805
[TBL] [Abstract][Full Text] [Related]
8. shRNA targeting Bmi1 impedes the self-renewal of cisplatin-enriched stem-like cells in human A549 cells.
Xu Y; Hu YD; Zhou J; Zhang MH; Yuan WW; Luo Y
Oncol Rep; 2012 Aug; 28(2):629-39. PubMed ID: 22664532
[TBL] [Abstract][Full Text] [Related]
9. Targeting of BMI-1 with PTC-209 inhibits glioblastoma development.
Kong Y; Ai C; Dong F; Xia X; Zhao X; Yang C; Kang C; Zhou Y; Zhao Q; Sun X; Wu X
Cell Cycle; 2018; 17(10):1199-1211. PubMed ID: 29886801
[TBL] [Abstract][Full Text] [Related]
10. The Role of Castration-Resistant Bmi1+Sox2+ Cells in Driving Recurrence in Prostate Cancer.
Yoo YA; Vatapalli R; Lysy B; Mok H; Desouki MM; Abdulkadir SA
J Natl Cancer Inst; 2019 Mar; 111(3):311-321. PubMed ID: 30312426
[TBL] [Abstract][Full Text] [Related]
11. Bmi1 regulates human glioblastoma stem cells through activation of differential gene networks in CD133+ brain tumor initiating cells.
Vora P; Seyfrid M; Venugopal C; Qazi MA; Salim S; Isserlin R; Subapanditha M; O'Farrell E; Mahendram S; Singh M; Bakhshinyan D; Chokshi C; McFarlane N; Dvorkin-Gheva A; Brown KR; Murty N; Moffat J; Bader GD; Singh SK
J Neurooncol; 2019 Jul; 143(3):417-428. PubMed ID: 31115870
[TBL] [Abstract][Full Text] [Related]
12. miR128-1 inhibits the growth of glioblastoma multiforme and glioma stem-like cells via targeting BMI1 and E2F3.
Shan ZN; Tian R; Zhang M; Gui ZH; Wu J; Ding M; Zhou XF; He J
Oncotarget; 2016 Nov; 7(48):78813-78826. PubMed ID: 27705931
[TBL] [Abstract][Full Text] [Related]
13. Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment.
Bolomsky A; Schlangen K; Schreiner W; Zojer N; Ludwig H
J Hematol Oncol; 2016 Mar; 9():17. PubMed ID: 26935956
[TBL] [Abstract][Full Text] [Related]
14. Hsp90α Mediates BMI1 Expression in Breast Cancer Stem/Progenitor Cells through Facilitating Nuclear Translocation of c-Myc and EZH2.
Lee YC; Chang WW; Chen YY; Tsai YH; Chou YH; Tseng HC; Chen HL; Wu CC; Chang-Chien J; Lee HT; Yang HF; Wang BY
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28914785
[TBL] [Abstract][Full Text] [Related]
15. Dysregulation of BMI1 and microRNA-16 collaborate to enhance an anti-apoptotic potential in the side population of refractory mantle cell lymphoma.
Teshima K; Nara M; Watanabe A; Ito M; Ikeda S; Hatano Y; Oshima K; Seto M; Sawada K; Tagawa H
Oncogene; 2014 Apr; 33(17):2191-203. PubMed ID: 23686310
[TBL] [Abstract][Full Text] [Related]
16. Silencing BMI1 radiosensitizes human breast cancer cells by inducing DNA damage and autophagy.
Griffith J; Andrade D; Mehta M; Berry W; Benbrook DM; Aravindan N; Herman TS; Ramesh R; Munshi A
Oncol Rep; 2017 Apr; 37(4):2382-2390. PubMed ID: 28260023
[TBL] [Abstract][Full Text] [Related]
17. Enhancing the therapeutic effect via elimination of hepatocellular carcinoma stem cells using Bmi1 siRNA delivered by cationic cisplatin nanocapsules.
Yang T; Chen Y; Zhao P; Xue H; You J; Li B; Liu Y; He C; Zhang X; Fan L; Lee RJ; Li L; Ma X; Xu C; Xiang G
Nanomedicine; 2018 Oct; 14(7):2009-2021. PubMed ID: 29842934
[TBL] [Abstract][Full Text] [Related]
18. YB-1 transforms human mammary epithelial cells through chromatin remodeling leading to the development of basal-like breast cancer.
Davies AH; Reipas KM; Pambid MR; Berns R; Stratford AL; Fotovati A; Firmino N; Astanehe A; Hu K; Maxwell C; Mills GB; Dunn SE
Stem Cells; 2014 Jun; 32(6):1437-50. PubMed ID: 24648416
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of BMI1 induces autophagy-mediated necroptosis.
Dey A; Mustafi SB; Saha S; Kumar Dhar Dwivedi S; Mukherjee P; Bhattacharya R
Autophagy; 2016; 12(4):659-70. PubMed ID: 27050456
[TBL] [Abstract][Full Text] [Related]
20. Knockdown of Bmi1 inhibits the stemness properties and tumorigenicity of human bladder cancer stem cell-like side population cells.
Zhu D; Wan X; Huang H; Chen X; Liang W; Zhao F; Lin T; Han J; Xie W
Oncol Rep; 2014 Feb; 31(2):727-36. PubMed ID: 24337040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
